Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 7/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.35 |
| ▸ | PDE1A | P54750 | 4/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800968 | 0.89 | EZH2 (0.35) | PDE1BPDE1CPDE1ACRHR1EZH2 | |
| SCHEMBL6798085 | 0.87 | CRHR1 (0.41) | PDE1BPDE1CPDE1ACRHR1 | |
| SCHEMBL6792201 | 0.83 | HSP90AA1 (0.41) | PDE1BPDE1CPDE1A | |
| SCHEMBL5844055 | 0.83 | PDE1B (0.36) | PDE1BPDE1CPDE1AEZH2 | |
| SCHEMBL6797534 | 0.83 | PDE1B (0.36) | PDE1BPDE1CPDE1AEZH2 | |
| SCHEMBL6798573 | 0.83 | BCL6 (0.37) | PDE1BPDE1CPDE1A | |
| SCHEMBL6799142 | 0.82 | LRRK2 (0.36) | PDE1BEZH2ADORA1 | |
| SCHEMBL6798514 | 0.82 | PDE1B (0.34) | PDE1BPDE1CPDE1ACRHR1EZH2 | |
| SCHEMBL6798508 | 0.82 | PDE1B (0.34) | PDE1BPDE1CPDE1ACRHR1EZH2 | |
| SCHEMBL6799139 | 0.82 | LRRK2 (0.36) | PDE1BEZH2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | PDE1B 2331/4885PDE1C 3016/4885PDE1A 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.